Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice

Inotropes are pharmacological agents that are indicated for the treatment of patients presenting with acute heart failure (AHF) with concomitant hypoperfusion due to decreased cardiac output. They are usually administered for a short period during the initial management of AHF until haemodynamic sta...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Vasiliki Bistola, Angelos Arfaras-Melainis, Eftihia Polyzogopoulou, Ignatios Ikonomidis, John Parissis
Formato: article
Lenguaje:EN
Publicado: Radcliffe Medical Media 2019
Materias:
Acceso en línea:https://doaj.org/article/0e11d0ccd47948c2b9b2449bc12d3d81
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:0e11d0ccd47948c2b9b2449bc12d3d81
record_format dspace
spelling oai:doaj.org-article:0e11d0ccd47948c2b9b2449bc12d3d812021-12-04T16:01:59ZInotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice10.15420/cfr.2019.11.22057-75592057-7540https://doaj.org/article/0e11d0ccd47948c2b9b2449bc12d3d812019-11-01T00:00:00Zhttps://www.cfrjournal.com/articles/Inotropes-in-Acute-Heart-Failurehttps://doaj.org/toc/2057-7540https://doaj.org/toc/2057-7559Inotropes are pharmacological agents that are indicated for the treatment of patients presenting with acute heart failure (AHF) with concomitant hypoperfusion due to decreased cardiac output. They are usually administered for a short period during the initial management of AHF until haemodynamic stabilisation and restoration of peripheral perfusion occur. They can be used for longer periods to support patients as a bridge to a more definite treatment, such as transplant of left ventricular assist devices, or as part of a palliative care regimen. The currently available inotropic agents in clinical practice fall into three main categories: beta-agonists, phosphodiesterase III inhibitors and calcium sensitisers. However, due to the well-documented potential for adverse events and their association with increased long-term mortality, physicians should be aware of the indications and dosing strategies suitable for different types of patients. Novel inotropes that use alternative intracellular pathways are under investigation, in an effort to minimise the drawbacks that conventional inotropes exhibit.Vasiliki BistolaAngelos Arfaras-MelainisEftihia PolyzogopoulouIgnatios IkonomidisJohn ParissisRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENCardiac Failure Review , Vol 5, Iss 3, Pp 133-139 (2019)
institution DOAJ
collection DOAJ
language EN
topic Diseases of the circulatory (Cardiovascular) system
RC666-701
spellingShingle Diseases of the circulatory (Cardiovascular) system
RC666-701
Vasiliki Bistola
Angelos Arfaras-Melainis
Eftihia Polyzogopoulou
Ignatios Ikonomidis
John Parissis
Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice
description Inotropes are pharmacological agents that are indicated for the treatment of patients presenting with acute heart failure (AHF) with concomitant hypoperfusion due to decreased cardiac output. They are usually administered for a short period during the initial management of AHF until haemodynamic stabilisation and restoration of peripheral perfusion occur. They can be used for longer periods to support patients as a bridge to a more definite treatment, such as transplant of left ventricular assist devices, or as part of a palliative care regimen. The currently available inotropic agents in clinical practice fall into three main categories: beta-agonists, phosphodiesterase III inhibitors and calcium sensitisers. However, due to the well-documented potential for adverse events and their association with increased long-term mortality, physicians should be aware of the indications and dosing strategies suitable for different types of patients. Novel inotropes that use alternative intracellular pathways are under investigation, in an effort to minimise the drawbacks that conventional inotropes exhibit.
format article
author Vasiliki Bistola
Angelos Arfaras-Melainis
Eftihia Polyzogopoulou
Ignatios Ikonomidis
John Parissis
author_facet Vasiliki Bistola
Angelos Arfaras-Melainis
Eftihia Polyzogopoulou
Ignatios Ikonomidis
John Parissis
author_sort Vasiliki Bistola
title Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice
title_short Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice
title_full Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice
title_fullStr Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice
title_full_unstemmed Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice
title_sort inotropes in acute heart failure: from guidelines to practical use: therapeutic options and clinical practice
publisher Radcliffe Medical Media
publishDate 2019
url https://doaj.org/article/0e11d0ccd47948c2b9b2449bc12d3d81
work_keys_str_mv AT vasilikibistola inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice
AT angelosarfarasmelainis inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice
AT eftihiapolyzogopoulou inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice
AT ignatiosikonomidis inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice
AT johnparissis inotropesinacuteheartfailurefromguidelinestopracticalusetherapeuticoptionsandclinicalpractice
_version_ 1718372718162739200